Treatment:

In case you suffer from congestive heart failure, the healthcare professional will monitor you closely. You would have follow-up appointments at least every 3 – 6 months and tests for checking your heart function. For instance, an echocardiogram (ultrasound of the heart) will be done once in a while to find out how well your heart is pumping blood with every beat.

You will have to monitor yourself carefully and help in managing the condition. An important way to do this is by tracking your weight on a daily basis. Weight gain could be a sign of fluid retention and that your condition is worsening. Ensure to weigh yourself at the same time everyday and on the same weight scale, with little or no clothes on. This will give you the exact weight.

Other Important Measures Comprise Of:

How It Works

Basic Overview:
There are certain basic principles that must be followed prior to the Regenerative Tissue Therapy (cells) infusion, especially in case of frozen Regenerative Tissue Therapy (cells).

To begin, the frozen Regenerative Tissue Therapy (cells) need to be thawed at 37 degrees Celsius, by constant agitation.

At the time of thawing, it is important that the Regenerative Tissue Therapy (cells) are not exposed to bright light.

The Regenerative Tissue Therapy (cells) then need to be collected in a syringe, which is ideally covered with a tape to avoid exposure to direct light. This is done with a wide bore needle to prevent any damage to the fragile Regenerative Tissue Therapy (cells).

The infusion needs to be administered over a period of three to five minutes, in dim light, with the help of a 23 gauge needle.

Check for immediate transfusion reaction.

Dosage and Mode of Administration of Regenerative Tissue Therapy (cells):

The Regenerative Tissue Therapy (cells) dosage varies on a case to case basis, ranging from 30 to 100 million Regenerative Tissue Therapy (cells) in order to generate apt results. Dose as low as 1 million may also be sufficient to produce a positive response.
We advocate intravenous mode of administration in majority of the cases. However, for special cases and specific disorders we even suggest intra-arterial, intramusclular, intrathecal, intraocular, subcutaneous, sub-dural, sub-arachnoid or even direct on-site delivery of Regenerative Tissue Therapy (cells). The Regenerative Tissue Therapy (cells) are administered on the exact site of injury either through direct implantantation (injection) on-site or using special interventional techniques.
The final decision on dosage as well as mode of administration of Regenerative Tissue Therapy (cells) is best taken after a through deliberation, the depending cause as well as extent of the concerned ailment. This decision must be taken on a case to case basis.

Treatment Details

Allogenic Umbilical Cord Derived Regenerative Tissue Therapy (cells):

Each dose of umbilical Regenerative Tissue Therapy (cells) must be preceded by GM-CSF a day prior to the Regenerative Tissue Therapy (cells) infusion. The dosage for this is 5 microgram / kg body weight in adults and 2.5 microgram / kg body weight in a child.

Mode of Administration of GM-CSF:

Endotoxin content

Autologous Bone Marrow Derived Regenerative Tissue Therapy (cells):
Approximately 150 to 200 ml of bone marrow is collected in a blood bag, using aseptic precautions. This is performed in an OT, under general anesthesia.

The Regenerative Tissue Therapy (cells) are then processed and isolated under the GLP and GMP standards.

A final volume of 5 to 10 ml is administered intravenously inside 6 to 8 hours from collection.

As the Regenerative Tissue Therapy (cells) cannot be tested for bacterial contamination, an antibiotic cover is necessary prior to infusion.

Mode of administration of Regenerative Tissue Therapy (cells): Intravenous

Autologous Regenerative Tissue Therapy (cells) Obtained from Adipose Tissue:

Approximately 150 to 200 ml adipose tissue is collected in a blood bag through liposuction. It is collected by a surgeon in an OT, under general anesthesia.

The collected Regenerative Tissue Therapy (cells) are then processed and isolated under the GLP and GMP standards.

A final volume of 5 to 10 ml is administered intravenously within 6 to 8 hours from collection.

Since these Regenerative Tissue Therapy (cells) cannot be tested for bacterial contamination, an antibiotic cover is required prior to the infusion.

Mode of Administration: Intravenous

Autologous Regenerative Tissue Therapy (cells) Obtained from Peripheral Blood:

The Regenerative Tissue Therapy (cells) are collected by using a procedure known as “apheresis”.

This procedure is performed in an ambient environment by using a well programmed cell separator (Hemonitics or Kobe Spectra) that provides the desired Regenerative Tissue Therapy (cells) in a specially designed blood bag. Approximately 200 to 250 ml Regenerative Tissue Therapy (cells) are derived from the blood stream.

Prior infusion of GM-CSF ensures maximum mobilization of essential Regenerative Tissue Therapy (cells) from the bone marrow. The dosage for this is 5 microgram / kg body weight in adults and 2.5 microgram / kg body weight in children.

Mode of Administration: Intravenous
Autologous Regenerative Tissue Therapy (cells) Derived from Skin, Teeth, Liver, Cornea, Small intestine, etc.

Regenerative Tissue Therapy (cells) from any of these organs are derived using sophisticated techniques to isolate them. This procedure is performed in an operation theatre, under general anesthesia.

The Regenerative Tissue Therapy (cells) are processed and isolated under the GLP and GMP standards.

A final volume of 5 to 10 ml is then administered intravenously within six to eight hours of collection.

Since it is not possible to test the Regenerative Tissue Therapy (cells) for bacterial contamination, an antibiotic cover is warranted prior to infusion.

Mode of Administration: Intravenous

Autologous / Allogenic Therapy using Regenerative Tissue Therapy (cells) Derived from Placenta, Amniotic Sac and / or Amniotic Fluid:

Various progenitor cell populations like mesenchymal, trophoblastic, hematopoietic and more primitive Regenerative Tissue Therapy (cells) can be isolated from the placenta and amniotic fluid. At least some of the amniotic as well as placental cells share a common origin like the inner cell mass of the morula. In fact, most progenitor cell types that can be isolated from these 2 sources share a number of characteristics. The placenta and amniotic fluid include multiple progenitor cell types from the developing embryo, including bone, fat and muscle.

Placenta and Amniotic Sac:

Following simultaneous harvesting of blood cells from the placenta blood (UPB), placenta tissue (UPT) umbilical cord (UCB) for their content of nucleated cells, the results showed that the nuclear cells (NC) from UPT and UPB have 3 to 4 times more cells than that from umbilical cord blood. In the long-term cell culture condition, the cells from UPT (Placental tissue) and UPB (Placental Blood) have more ability to survive in comparison to cells from UCB (Cord Blood).

The cells stored in liquid nitrogen did not show a major loss in total nucleated cell count as well as CD34 (+) cells. It was also observed that the UPB and UPT possessed more suppressor lymphocytes, which can prove important in the prevention of graft-versus-host disease. Such implications advocate the importance of placental blood and tissue collection, and their processing along with umbilical cord blood for the transplanting of Regenerative Tissue Therapy (cells).

Amniotic Fluid:

Regenerative Tissue Therapy (cells) derived from amniotic fluid have been utilized to differentiate into bone, muscle, cartilage, adipose tissue, nerve, blood vessel, etc. These cells offer a valuable resource for organ, cell, and tissue repair.

Regenerative Tissue Therapy (cells) sourced from the amniotic fluid are referred to as AFS (Amniotic Fluid Derived Stem) cells. They may be an intermediate stage between the embryonic Regenerative Tissue Therapy (cells) and adult cells. These cells are competent of extensive self-renewal, which is a defining property of Regenerative Tissue Therapy (cells). They can even be used to generate a vast range of cells that could prove valuable for therapy.

Amniotic Fluid Derived Regenerative Tissue Therapy (cells) can be obtained from large supplies of amniotic fluid, by using the many procedures that examine cells for the prenatal diagnosis of certain genetic disorders. This procedure is known as amniocentesis. Even childbirth is considered a source of amniotic fluid. The possibility for a perfect match is also likely due to its primitive nature.

Advantages of AFS Cells:
They can be easily obtained through amniocentesis.

Since they double every 36 hours, they can be grown in large amounts to produce large quantities of Regenerative Tissue Therapy (cells).

The specialized cells generated from AFS cells contain all three types of cells, which exist in the developing mesoderm, embryo – ectoderm and endoderm. Consequently, these Regenerative Tissue Therapy (cells) can differentiate into any organ, cell or tissue in the body.

There is no need for ‘Feeders’ or ‘Factors’ to guide them to towards the desired cell line.

They don’t cause tumors and therefore are preferred over embryonic Regenerative Tissue Therapy (cells).

Similar to embryonic Regenerative Tissue Therapy (cells), Amniotic Fluid Derived Regenerative Tissue Therapy (cells) have the potential of generating all types of adult cells.

The project director also recommends the use of Regenerative Tissue Therapy (cells) derived from the placenta, amniotic sac and/or amniotic fluid. These Regenerative Tissue Therapy (cells) are carefully processed, isolated as well as cultured in a clean room, using GLP and GMP standards. They can be utilized for allogenic or autologous use, similar to Regenerative Tissue Therapy (cells) that have been isolated from the cord blood and cord tissue.

At times, this is done concurrently with hyperbaric oxygen and/or Chelation therapy, after prior administration of GM- CSF. The selection of Regenerative Tissue Therapy (cells), the dose, source, mode of administration and accompanying concurrent therapy can vary on a case to case basis.

Mode of Administration of Regenerative Tissue Therapy (cells): Intravenous

Possible Side Effects of Amniotic Regenerative Tissue Therapy (cells):

Outlook (Prognosis):

Congestive cardiac failure is a serious disorder. It is a chronic disease, which can become worse with infections or other physical stress. Several forms of heart failure can be controlled with the help of lifestyle changes, medication as well as treatment of the underlying disorder.

Possible Complications:

Call your healthcare professional if you develop unexplained symptoms such as increased cough or production of sputum, weakness, swelling, or sudden weight gain.

Contact the local emergency service or dial 911 if you experience fainting spells, severe chest pain or rapid and irregular heartbeat (especially if other symptoms accompany a rapid or irregular heartbeat).

Prevention: